Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1996 Dec;87(12):1251–1258. doi: 10.1111/j.1349-7006.1996.tb03140.x

Induction by Interleukin‐15 of Human Killer Cell Activity against Lung Cancer Cell Lines and Its Regulatory Mechanisms

Eiji Takeuchi 1, Hiroaki Yanagawa 1, Seiji Yano 1, Takashi Haku 1, Saburo Sone 1,✉
PMCID: PMC5921031  PMID: 9045960

Abstract

Interleukin (IL)‐15 is a novel cytokine with IL‐2‐like activity. In the present study, we examined IL‐15‐mediated induction of killer activity of peripheral blood mononuclear cells (MNC) against lung cancer cell lines, and the regulatory mechanisms of this induction by IL‐15. Cytotoxic activity was measured by 51Cr release assay. IL‐15 at concentrations of more than 10 ng/ml induced significant killer activity of blood MNC against a small cell lung cancer cell line (SBC‐3), as well as Daudi cells, and 50 ng/ml was considered its optimal concentration. A time course study revealed that an incubation period of 4–6 days was optimal for induction of killer activity. MNC cultured with IL‐15 also exhibited killer activity against other lung cancer cell lines (H‐69, N‐291 and PC‐9 cells). IL‐15 and IL‐12 had additive effects on induction of killer activity against SBC‐3 cells. On the other hand, IL‐15 had no synergistic or additive effect on induction of killer activity by IL‐2. Fresh human monocytes isolated by centrifugal elutriation augmented the development of killer activity of lymphocytes stimulated by IL‐15. As a humoral regulatory factor, IL‐4 had a suppressive effect on induction of killer activity by IL‐15. IFN‐γ, IL‐1β, TNF‐α, IL‐6 or IL‐10 had no effect on induction of killer activity by IL‐15 at the optimal concentration. These results suggest that IL‐15 has potential for the immunotherapy of ling cancer.

Keywords: Interleukin‐15, Mononuclear cell, Tumor cytotoxicity, Lymphokine‐activated killer cell

Full Text

The Full Text of this article is available as a PDF (481.3 KB).

REFERENCES

  • 1. ) Ries , L. G. , Pollack , E. S. and Young , J. L.Cancer patient survival: surveillance, epidermiology and end results program, 1973–79 . J. Natl. Cancer Inst. , 70 , 693 – 707 ( 1983. ). [PubMed] [Google Scholar]
  • 2. ) Paesmans , M. , Sculier , J. P. , Libert , P. , Bureau , G. , Dabouis , G. , Thiriaux , J. , Michel , J. , Cutsem , O. V. , Sergysels , R. , Mommen , P. and Klastersky , J.Prognostic factors for survival in advanced non‐small‐cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients . J. Clin. Oncol. , 13 , 1221 – 1230 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Rosenberg , S. A. , Lotze , M. T. , Muul , L. M. , Chang , A. E. , Avis , F. P. , Leitman , S. , Linehan , W. M. , Robertson , C. N. , Lee , R. E. , Rubin , J. T. , Seipp , C. A. , Simpson , C. G. and White , D. E.A progress report on the treatment of 157 patients with advanced cancer using lymphokine‐activated killer cells and interleukin‐2 or high‐dose interleukin‐2 alone . N. Engl. J. Med. , 316 , 889 – 897 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Yang , S. C. , Owen‐Schaub , L. , Grimm , E. A. and Roth , J. A.Induction of lymphokine‐activated killer cytotoxicity with interleukin‐2 and tumor necrosis factor‐alpha against primary lung cancer targets . Cancer Immunol. Immunother. , 29 , 193 – 198 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. ) Valone , F. H. , Gandara , D. R. , Deisseroth , A. B. , Perez , E. A. , Rayner , A. , Aronson , F. R. , Luce , J. and Paradise , C.Interleukin‐2, cisplatin, and 5‐fluorouracil for patients with non‐small cell lung and head/neck carcinomas . J. Immunother. , 10 , 207 – 213 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Lissoni , P. , Meregalli , S. , Fossati , V. , Paolorossi , F. , Barni , S. , Tancini , G. and Frigerio , F.A randomized study of immunotherapy with low‐dose subcutaneous interleukin‐2 plus melatonin vs chemotherapy with cisplatin and etoposide as first‐line therapy for advanced non‐small cell lung cancer . Tumori , 80 , 464 – 467 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Grabstein , K. H. , Eisenman , J. , Shanebeck , K. , Rauch , C. , Srinivasan , S. , Fung , V. , Beers , C. , Richardson , J. , Schoenborn , M. A. , Ahdieh , M. , Johnson , L. , Alderson , M. R. , Watson , J. D. , Anderson , D. M. and Giri , J. G.Cloning of a T cell growth factor that interacts with the β‐chain of the interleukin‐2 receptor . Science , 264 , 965 – 967 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Bruton , J. D. , Bamford , R. N. , Peters , C. , Grant , A. J. , Kurys , G. , Goldman , C. K. , Brennan , J. , Roessler , E. and Waldmann , T. A.A lymphokine, provisionally designated interleukin T and produced by a human adult T cell leukemia line, stimulates T cell proliferation and the induction of lymphokine‐activated killer cells . Proc. Natl. Acad. Sci. USA , 91 , 4935 – 4939 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ) Bamford , R. N. , Grant , A. J. , Burton , J. D. , Peters , C. , Kurys , G. , Goldman , C. K. , Brennan , J. , Roessler , E. and Waldmann , T. A.The interleukin (IL) 2 receptor β‐chain is shared by IL‐2 and a cytokine provisionally designated IL‐T, that stimulates T cell proliferation and the induction of lymphokine activated killer cells . Proc. Natl. Acad. Sci. USA , 91 , 4940 – 4944 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. ) Carson , W. E. , Giri , J. G. , Lindemann , M. J. , Linett , M. L. , Ahdieh , M. , Paxton , R. , Anderson , D. , Eisenmann , J. , Grabstein , K. and Caligiuri , M. A.Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL‐2 receptor . J. Exp. Med. , 180 , 1395 – 1403 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. ) Armitage , R. J. , Macduff , B. M. , Eisenman , J. , Paxton , R. and Grabstein , K. H.IL‐15 has stimulatory activity for the induction of B cell proliferation and differentiation . J. Immunol. , 154 , 483 – 490 ( 1995. ). [PubMed] [Google Scholar]
  • 12. ) Wilkinson , P. C. and Liew , F. Y.Chemoattraction of human blood T lymphocytes by IL‐15 . J. Exp. Med. , 181 , 1255 – 1259 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. ) Gamero , A. M. , Ussery , D. , Reintgen , D. S. , Puleo , C. A. and Djeu , J. Y.Interleukin 15 induction of lymphokine‐activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18‐dependent, perforin‐related mechanism . Cancer Res. , 55 , 4988 – 4994 ( 1995. ). [PubMed] [Google Scholar]
  • 14. ) Yonei , T. , Ohnoshi , T. , Hiraki , S. , Ueoka , H. , Kiura , K. , Moritaka , T. , Shibayama , T. , Tabata , M. , Segawa , Y. and Takigawa , N.Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens . Acta Med. Okayama , 47 , 233 – 241 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Sone , S. , Inamura , N. , Nii , A. and Ogura , T.Heterogeneity of human lymphokine (IL‐2)‐activated killer (LAK) precursors and regulation of their LAK induction by blood monocytes . Int. J. Cancer , 42 , 428 – 434 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Kato , K. , Yamada , T. , Kawahara , K. , Onda , H. , Asano , T. , Sugino , H. and Kakinuma , A.Purification and characterization of recombinant human interleukin‐2 produced in Escherichia coli . Biochem. Biophys. Res. Commun. , 130 , 692 – 699 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Haku , T. , Sone , S. , Nabioullin , R. and Ogura , T.Human alveolar macrophages augment natural killer cell stimulatory factor (interleukin‐12)‐inducible killer activity from autologous blood lymphocytes . Jpn. J. Cancer Res. , 86 , 81 – 87 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. ) Nabioullin , R. , Sone , S. , Nii , A. , Haku , T. and Ogura , T.Induction mechanism of human blood CD8+ T cell proliferation and cytotoxicity by natural killer cell stimulatory factor (interleukin‐12) . Jpn. J. Cancer Res. , 85 , 853 – 861 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. ) Sone , S. , Utsugi , T. , Nii , A. and Ogura , T.Differential effects of recombinant interferons α, β, and γ on induction of human lymphokine (IL‐2)‐activated killer activity . J. Natl. Cancer Inst. , 80 , 425 – 431 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Han , X.Itoh , K. , Balch , C. M. and Pellis , N. R.Recombinant interleukin 4 (rIL‐4) inhibits interleukin 2‐induced activation of peripheral blood lymphocytes . Lymphokine Res. , 7 , 227 – 235 ( 1988. ). [PubMed] [Google Scholar]
  • 21. ) Kawakami , Y. , Custer , M. , Rosenberg , S. A. and Lotze , M. T.IL‐4 regulates IL‐2 induction of lymphokine‐activated killer activity from human lymphocytes . J. Immunol. , 142 , 3452 – 3461 ( 1989. ). [PubMed] [Google Scholar]
  • 22. ) Sone , S. , Utsugi , T. , Nii , A. and Ogura , T.Effects of human alveolar macrophages on the induction of lymphokine (IL 2) activated killer cells . J. Immunol. , 139 , 29 – 34 ( 1987. ). [PubMed] [Google Scholar]
  • 23. ) Nii , A. , Sone , S. , Utsugi , T. , Yanagawa , H. and Ogura , T.Up‐ and down‐regulation of human lymphokine (IL‐2)‐activated killer cell induction by monocytes, depending on their functional state . Int. J. Cancer , 41 , 33 – 40 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Sone , S. , Kunishige , E. , Fawzy , F. , Yanagawa , H. , Nii , A. , Maeda , K. , Atagi , S. , Heike , Y. , Nishioka , Y. , Mizuno , K. and Ogura , T.Interleukin‐2‐inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients . Jpn. J. Cancer Res. , 82 , 716 – 723 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. ) Giri , J. G. , Kumaki , S. , Ahdieh , M. , Friend , D. J. , Loomis , A. , Shanebeck , K. , Dubose , R. , Cosman , D. , Park , L. S. and Anderson , D. M.Identification and cloning of a novel IL‐15 binding protein that is structurally related to the α chain of the IL‐2 receptor . EMBO J. , 14 , 3654 – 3663 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. ) Yang , S. S. , Malek , T. R. , Hargrove , M. E. and Ting , C.Lymphokine‐induced cytotoxicity: requirement of two lymphokines for the induction of optimal cytotoxic responses . J. Immunol. , 134 , 3912 – 3919 ( 1985. ). [PubMed] [Google Scholar]
  • 27. ) Wakasugi , H. , Bertoglio , J. , Tursz , T. and Fradelizi , D.IL‐2 receptor induction on human T lymphocytes: role for IL‐2 and monocytes . J. Immunol. , 135 , 321 – 327 ( 1985. ). [PubMed] [Google Scholar]
  • 28. ) Ochoa , A. C. , Gromo , G. , Alter , B. J. , Sondel , P. M. and Bach , F. H.Long term growth of lymphokine‐activated killler (LAK) cells: role of anti‐CD‐3, β‐IL‐1, interferon‐γ and ‐β . J. Immunol. , 138 , 2728 – 2733 ( 1987. ). [PubMed] [Google Scholar]
  • 29. ) Owen‐Schaub , L. B. , Gutterman , J. U. and Grimm , E. A.Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor α and interleukin 2 in the generation of human lymphokine‐activated killer cell cytotoxicity . Cancer Res. , 48 , 788 – 792 ( 1988. ). [PubMed] [Google Scholar]
  • 30. ) Smyth , M. J. , Ortaldo , J. R. , Bere , W. , Yagita , H. , Okamura , K. and Young , H. A.IL‐2 and IL‐6 synergize to augment the pore‐forming protein gene expression and cytotoxic potential of human peripheral blood T cells . J. Immunol. , 145 , 1159 – 1166 ( 1990. ). [PubMed] [Google Scholar]
  • 31. ) Hsu , D. H. , Moore , K. W. and Spits , H.Differential effects of IL‐4 and IL‐10 on IL‐2‐induced IFN‐γ synthesis and lymphokine‐activated killer activity . Int. Immunol. , 4 , 563 – 569 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Horing , H. , Zuber , M. , Garotta , G. and Heberer , M.On the relative roles of interleukin‐2 and interleukin‐10 in the generation of lymphokine‐activated killer cell activity . Cell. Immunol. , 146 , 391 – 405 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Martinez , O. M. , Gibbons , R. S. , Garovoy , M. R. and Aronson , F. R.IL‐4 inhibits IL‐2 receptor expression and IL‐2‐dependent proliferation of human T cells . J. Immunol. , 144 , 2211 – 2215 ( 1990. ). [PubMed] [Google Scholar]
  • 34. ) Bich‐Thuy , L. T. , Dukovich , M. , Peffer , N. J. , Fauci , A. S. , Kehrl , J. H. and Greene , W. C.Direct activation of human resting T cells by IL‐2: the role of an IL‐2 receptor distinct from the Tac protein . J. Immunol. , 139 , 1550 – 1556 ( 1987. ). [PubMed] [Google Scholar]
  • 35. ) Sharon , M. , Siegel , J. P. , Tosato , G. , Yodoi , J. , Gerrard , T. L. and Leonard , W. J.The human interleukin 2 receptor β chain (p70): direct identification, partial purification, and patterns of expression on peripheral blood mononuclear cells . J. Exp. Med. , 167 , 1265 – 1270 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. ) Siegel , J. P. , Sharon , M. , Smith , P. L. and Leonard , W. J.The IL‐2 receptor β chain (P70): role in mediating signals for LAK, NK, and proliferative activities . Science , 238 , 75 – 78 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 37. ) Tsudo , M. , Goldman , C. K. , Bongiovanni , K. F. , Chan , W. C. , Winton , E. F. , Yagita , M. , Grimm , E. A. and Waldmann , T. A.The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells . Proc. Natl. Acad. Sci. USA , 84 , 5394 – 5398 ( 1987. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. ) Kondo , M. , Takeshita , T. , Ishii , N. , Nakamura , M. , Watanabe , S. , Arai , K. and Sugamura , K.Sharing of the interleukin‐2 (IL‐2) receptor γ chain between receptors for IL‐2 and IL‐4 . Science , 262 , 1874 – 1877 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 39. ) Takeshita , T. , Asao , H. , Ohtani , K. , Ishii , N. , Kumaki , S. , Tanaka , N. , Munakata , H. , Nakamura , M. and Sugamura , K.Cloning of the γ chain of the human IL‐2 receptor . Science , 257 , 379 – 382 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 40. ) Giri , J. G. , Ahdieh , M. , Eisenman , J. , Shanebeck , K. , Grabstein , K. , Kumaki , S. , Namen , A. , Park , L. S. , Cosman , D. and Anderson , D.Utilization of the β and γ chains of the IL‐2 receptor by the novel cytokine IL‐15 . EMBO J. , 13 , 2822 – 2830 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES